Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)

por Escribano-Subias, Pilar, Bendjenana, Hakim, Curtis, Paula S., Lang, Irene, Noordegraaf, Anton Vonk
Publicado 2019

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes:...

por Komajda, Michel, Curtis, Paula, Hanefeld, Markolf, Beck-Nielsen, Henning, Pocock, Stuart J, Zambanini, Andrew, Jones, Nigel P, Gomis, Ramon, Home, Philip D
Publicado 2008

Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

por Komajda, Michel, McMurray, John J.V., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., Jones, Nigel P., Home, Philip D.
Publicado 2010

Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea

por Tanaka, Yoshiya, Bae, Sang-Cheol, Bass, Damon, Curtis, Paula, Chu, Myron, DeRose, Kathleen, Ji, Beulah, Kurrasch, Regina, Lowe, Jenny, Meizlik, Paige, Roth, David A
Publicado 2021

Incidence and Prevalence of Unrecognized Myocardial Infarction in People With Diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in...

por MacDonald, Michael R., Petrie, Mark C., Home, Philip D., Komajda, Michel, Jones, Nigel P., Beck-Nielsen, Henning, Gomis, Ramon, Hanefeld, Markolf, Pocock, Stuart J., Curtis, Paula S., McMurray, John J.V.
Publicado 2011

The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study

por Bae, Sang-Cheol, Bass, Damon L., Chu, Myron, Curtis, Paula, Dimelow, Richard, Harvey, Laurence, Ji, Beulah, Kurrasch, Regina, Muzaffar, Saima, Punwaney, Raj, Roth, David A., Song, Yeong-Wook, Xie, Wendy, Zhang, Fengchun
Publicado 2022

Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years

por Zhang, Fengchun, Zheng, Jie, Li, Yang, Wang, Guochun, Wang, Mingjun, Su, Yin, Gu, Jieruo, Li, Xingfu, Bass, Damon, Chu, Myron, Curtis, Paula, DeRose, Kathleen, Kurrasch, Regina, Lowe, Jenny, Meizlik, Paige, Roth, David A
Publicado 2022